Table 1.

H₂S-releasing substances.

Substance	Concentration	Cells	Effect	Comment	Ref.
NaHS	0.2–0.4 mM	Lymphocytes (CD8+, NK)	Apoptosis ↑	Caspase independent, glutathione dependent	[112]
NaHS	10–75 µM	Lung fibroblasts	Apoptosis ↑	12–48 h	[113]
NaHS	10, 100, 300 µM	Neutrophils (mice)	(MIP-2 induced) chemotaxis ↑		[72]
NaHS	10 mM	Jurkat	Apoptosis ↑ (caspase 9)	15 min	[114]
NaHS	10–1000 µM	HUVEC 3T3 fibroblasts	(IRI-induced) apoptosis ↓		[115]
NaHS	0.23–3.66 mM	Neutrophils	Apoptosis ↓		[80]
NaHS	100, 500, 1000 µM	Endothelial cells	Apoptosis ↑	“100 µM safe in vitro concentration”	[54]
NaHS	100, 200 µM	RAW 264.7	LPS-stimulated PGE2- biosynthesis ↓	↑ (n.s.) at 1000 µM, “biphasic effect”	[52]
Na2S	100 µM	SMC	Ca2+ release ↓		[116]
Na2S	25 µM	Neutrophils	NETosis	PMA-induced	[117]
DATS	100, 200 µM	HepG2	H2O2 ↑	not for DADS	[118]
DATS	100 µM	HepG2	Caspase 3 ↑	not for DADS	[118]
DATS	20 µM	U937	Apoptosis ↑	not in THP-1, HL-60, K562 cells	[119]
DATS	1–10 µM	Cardiomyocytes	Glucose-induced apoptosis ↓ ROS ↓	NFκB ↓	[87]
DATS	100 µM	Pancreatic cancer cells	Apoptosis ↑		[120]
DATS	5, 10 µM	Cardiomyocytes	Glucose-induced apoptosis ↓		[86]
DATS	1–5 µM	WEHI-3	Apoptosis ↑		[121]
DATS	12, 24 µM	Rat hepatic stellate cells	Apoptosis ↑		[122]
DATS	10–100 µm	“several human cancer cells”	Apoptosis ↑		[122]
DATS	20, 40 µM (5–120 µM)	Human osteosarcoma cells	Apoptosis ↑ ROS ↑		[82]
DATS	0–50 µM	Primary effusion lymphoma cells	Apoptosis ↑		[81]
DATS	1–5 µM	Ethanol-stimulated L02	Apoptosis ↓ ROS ↓		[123]
DADS	5–50 µM	Lung fibroblasts	Proliferation ↓		[124]
DADS	5–300 µM	KG1α	Apoptosis ↑	24, 48, 72 h	[84]
DADS	1–100 µM	C28I2 Chondrocytes	(IL1β-induced) ROS ↓ (mitochondrial) apoptosis ↓	2–24 h 25 µM after 24 h not cytotoxic	[125]
DADS	1, 5, 10 µg/ml	BAR-T cells	Apoptosis ↑ (DCA-induced) ROS ↓	1, 3, 6, 12 h	[76]
DADS	25–250 µM	A549	Apoptosis ↑ ROS ↑		[126]
DADS	10, 20 mg/l	HL-60	Apoptosis ↑ ROS ↑		[85]
Cysteine	10 mM	SMC	Ca2+ release ↓		[116]
Cysteine	10–1000 µM	Neutrophils	[Ca2+]i ↑		[127]
GYY4137	1 mM	Hoxb8 neutrophils	ROS ↓ Endothelial transmigration ↓		[77]
GYY4137	200 µM	Neutrophils	(LPS stim.) ROS ↓ (LPS inhibited) apoptosis ↑		[128]
GYY4137	500 µM	RAW264.7cells	NF-κB activation (LPS) ↓		[129]
GYY4137	400 µM	MCF-7	Apoptosis	Not for IMR90 cells	[130]
GYY4137	100–1000 µM	RAW 264.7	LPS-stimulated PGE2-, NO2−-, TNFα-, IL-1β- biosynthesis ↓		[52]

HepG2: human hepatoblastoma cells. U937: human leukemia cells. WEHI-3: murine leukemia cells. L-02: human fetal hepatocyte line. KG1α: leukemia cell line. BAR-T cells: Barrett’s carcinoma precursor epithelial cells. A549: lung cancer cells. Hoxb8 neutrophils: conditionally HoxB8-immortalized mouse hematopoietic progenitors are suitable for in vitro differentiation of a range of myeloid cells, including neutrophils. RAW264.7cells: monocyte/macrophage-like cells, originating from Abelson leukemia virus transformed cell line derived from BALB/c mice. MCF-7 cells: epithelial cell line isolated from the breast tissue of a patient with metastatic adenocarcinoma. IMR90 cells: normal human lung fibroblasts. RAW 264.7: murine macrophages. IRI: Ischemia-reperfusion injury. The arrows ↑ and ↓ indicate increase and decrease, respectively, of the indicated parameter. n.s.: non-significant.